Overview

Temsirolimus in Myelodysplastic Syndrome (MDS)

Status:
Terminated

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The goal of this Pilot-study is to evaluate the response of unselected MDS patients to temsirolimus a drug approved for the treatment of renal cell cancer. It is planned to give temsirolimus at a weekly dose of 25 mg as intravenous infusion for a maximum duration of 12 months. Regular bone marrow biopsies are planned for controlling MDS response.

Phase:

Phase 2

Details

Lead Sponsor:

Technische Universität Dresden

Collaborator:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Everolimus
Sirolimus